ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications

Permanent lenke
https://hdl.handle.net/10037/13324
DOI
https://doi.org/10.1016/j.blre.2017.05.001
Thumbnail
Åpne
article.pdf (804.3Kb)
Publisher's version (PDF)
Dato
2017-05-03
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Arranz, Lorena; Arriero Sanchez, Maria Del Mar; Villatoro, Alicia
Sammendrag
Interleukin-1β (IL-1β) is a pleiotropic cytokine that exerts multiple roles in both physiological and pathological conditions. It is produced by different cell subsets, and drives a wide range of inflammatory responses in numerous target cells. Enhanced IL-1β signaling is a common event in patients of hematological malignancies. Recent body of evidence obtained in preclinical models shows the pathogenic role of these alterations, and the promising therapeutic value of IL-1 targeting. In this review, we further highlight a potential contribution of IL-1β linking to complications and autoimmune disease that should be investigated in future studies. Hence, drugs that target IL-1 may be helpful to improve outcome or reduce morbidity in patients. Some of them are FDA-approved, and used efficiently against autoimmune diseases, like IL-1 receptor antagonist. In the clinic, however, this agent seems to have limited properties. Current improved drugs will allow to determine the true potential of IL-1 and IL-1β targeting as therapy in hematological malignancies and their related complications.
Er en del av
Villatoro, A. (2022). The role of interleukin-1 receptor antagonist in normal and malignant hematopoiesis. (Doctoral thesis). https://hdl.handle.net/10037/26329
Forlag
Springer Verlag (Germany)
Sitering
Arranz, L., Arriero Sanchez, M.D.M. & Villatoro, A.E. (2017). Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications. Blood reviews, 31(5), 306-317. https://doi.org/10.1016/j.blre.2017.05.001
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (medisinsk biologi) [1103]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring